Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

New Zealand Blackcurrant and Recovery in Elite Taekwondo (NZBC-TAE)

17 september 2026 uppdaterad av: Sedat Arslan, Hacettepe University

Effects of New Zealand Blackcurrant Extract Supplementation on Muscle Damage, Oxidative Stress, and Inflammatory Markers Following High-Intensity Training in Elite Taekwondo Athletes

This randomized, double-blind, placebo-controlled trial evaluated the effects of short-term supplementation with anthocyanin-rich New Zealand blackcurrant (NZBC) extract on exercise-induced muscle damage, oxidative stress, antioxidant status, inflammatory responses, and perceived muscle soreness in elite male taekwondo athletes.

Thirty national-level male taekwondo athletes were enrolled and randomly assigned in a 1:1 ratio to receive either NZBC extract (CurraNZ®, UK; 600 mg/day providing approximately 210 mg anthocyanins) or a matched placebo for 7 days. Blood samples and muscle soreness ratings were collected at baseline, immediately after exercise, 24 hours after exercise, and after 7 days.

The primary outcome was plasma creatine kinase (CK). Secondary outcomes included reactive oxygen species (ROS), total antioxidant capacity (TOAC), protein carbonyls, inflammatory cytokines (IL-6, TNF-α, and IL-10), and perceived muscle soreness assessed using a visual analog scale (VAS).

The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). Written informed consent was obtained from all participants.

Studieöversikt

Detaljerad beskrivning

High-intensity, impact-based sports such as taekwondo involve substantial mechanical and metabolic demands that may contribute to exercise-induced muscle damage, oxidative stress, inflammatory responses, and delayed recovery. Nutritional strategies capable of modulating these physiological responses may therefore be relevant for athletes exposed to repeated high-intensity training.

New Zealand blackcurrant (Ribes nigrum L.) is rich in anthocyanins and other polyphenolic compounds with antioxidant and anti-inflammatory properties. Previous studies involving endurance and intermittent exercise have investigated the potential effects of blackcurrant supplementation on oxidative stress, vascular responses, exercise performance, and recovery. However, evidence in elite combat-sport athletes remains limited.

The objective of this randomized controlled trial was to determine whether 7 days of standardized NZBC extract supplementation influenced biochemical markers of muscle damage, oxidative stress, antioxidant status, inflammatory cytokines, and perceived muscle soreness following repeated high-intensity training in elite male taekwondo athletes.

It was hypothesized that NZBC supplementation would attenuate exercise-associated elevations in plasma creatine kinase and reactive oxygen species, increase total antioxidant capacity, and modulate inflammatory cytokine responses, including IL-6, TNF-α, and IL-10.

The study used a randomized, double-blind, placebo-controlled, parallel-group design and was conducted at the Atik Ali Sports Club in Istanbul, Türkiye, between December 2023 and June 2024. Thirty elite male taekwondo athletes were enrolled and randomly allocated in a 1:1 ratio to receive either NZBC extract or placebo.

Participants assigned to the intervention group received 600 mg/day of New Zealand blackcurrant extract (CurraNZ®, UK), providing approximately 210 mg of anthocyanins, for 7 consecutive days. Participants assigned to the control group received a visually matched maltodextrin placebo. Randomization, allocation concealment, and blinding procedures were maintained throughout the intervention and until database lock.

Blood samples were collected at baseline, immediately following exercise, 24 hours after exercise, and after 7 days. Biochemical outcomes included plasma creatine kinase, reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, and TNF-α. Biomarkers were assessed using commercially available laboratory assay kits. Perceived muscle soreness was evaluated using a visual analog scale. Dietary intake and anthropometric characteristics were also assessed.

The primary outcome was the change in plasma creatine kinase. Secondary outcomes included reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, TNF-α, and perceived muscle soreness.

Statistical analyses were conducted using R version 4.3.1. Data distribution was assessed using the Shapiro-Wilk test, and homogeneity of variance was evaluated using Levene's test. Between-group comparisons were planned using independent-samples t-tests or Mann-Whitney U tests, as appropriate. Longitudinal changes were evaluated using repeated-measures analysis of variance, including group, time, and group × time interaction effects. Greenhouse-Geisser corrections were applied where assumptions of sphericity were not met. Sensitivity analyses were conducted using linear mixed-effects models. Statistical significance was defined as a two-tailed alpha level of 0.05.

The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). All participants provided written informed consent before participation.

Studietyp

Interventionell

Inskrivning (Faktisk)

29

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 35 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  • Male national-level taekwondo athletes actively training and competing
  • Age between 18 and 35 years
  • Free from any chronic disease, metabolic disorder, or recent musculoskeletal injury
  • Not using antioxidant, anti-inflammatory, or ergogenic supplements within the last 4 weeks
  • Willing to maintain regular diet and training schedule during the study period
  • Provided written informed consent

Exclusion Criteria:

  • Female athletes
  • Presence of chronic illness, injury, or infection
  • Use of antioxidant or anti-inflammatory supplements in the 4 weeks prior to enrollment
  • Dietary habits incompatible with the intervention (e.g., high anthocyanin intake from other sources)
  • Failure to complete all study visits or provide required blood samples
  • Withdrawal of consent at any time

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: New Zealand Blackcurrant Extract (NZBC)

Participants received New Zealand blackcurrant extract capsules (CurraNZ®, Healthspan Elite, UK) for 7 days. The daily dose was 600 mg (two 300 mg capsules, morning and evening), providing approximately 210 mg anthocyanins per day.

Standardized anthocyanin-rich blackcurrant extract administered orally at 600 mg/day (two 300 mg capsules) for 7 consecutive days. Each capsule contained natural polyphenolic compounds standardized to ~35% anthocyanins.

Placebo-jämförare: Placebo

Participants received placebo capsules identical in appearance to the NZBC capsules, containing maltodextrin. The placebo was administered orally twice daily for 7 days.

Two identical capsules containing maltodextrin, taken daily for 7 days (morning and evening), matching the NZBC supplementation schedule.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in plasma Creatine Kinase (CK) concentration
Tidsram: Baseline, immediately post-exercise, 24 hours, and 7 days after training

Plasma creatine kinase (CK) activity measured via ELISA assay as a biomarker of exercise-induced muscle damage. The outcome represents the change in CK levels from baseline to 24 h and 7 d after repeated high-intensity training sessions.

Baseline, immediately post-exercise, 24 hours, and 7 days after training

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Reactive Oxygen Species (ROS) levels
Tidsram: Baseline, immediately post-exercise, 24 hours, and 7 days

ROS concentrations measured by ELISA to assess oxidative stress response following high-intensity training.

Baseline, immediately post-exercise, 24 hours, and 7 days
Change in Total Antioxidant Capacity (TOAC)
Tidsram: Baseline, 24 hours, and 7 days

Total antioxidant capacity determined spectrophotometrically using commercial assay kits (Sunredbio, China). Reflects systemic antioxidant defense.

Baseline, 24 hours, and 7 days
Change in Inflammatory Cytokines (IL-6, TNF-α, IL-10)
Tidsram: Baseline, 24 hours, and 7 days

Serum IL-6, TNF-α, and IL-10 quantified by ELISA to evaluate systemic inflammatory and anti-inflammatory responses to exercise and supplementation.

Baseline, 24 hours, and 7 days
Perceived Muscle Soreness (Visual Analog Scale, VAS)
Tidsram: Baseline, 12 hours, 24 hours after each training day, and 7 days

Subjective muscle soreness assessed using a 10-cm visual analog scale (VAS), where 0 = no soreness and 10 = extreme soreness.

Baseline, 12 hours, 24 hours after each training day, and 7 days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 december 2023

Primärt slutförande (Faktisk)

1 juni 2024

Avslutad studie (Faktisk)

30 juni 2024

Studieregistreringsdatum

Först inskickad

14 september 2026

Först inskickad som uppfyllde QC-kriterierna

17 september 2026

Första postat (Faktisk)

18 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Individual participant data (IPD) that underlie the results reported in this article (deidentified participant data, including baseline characteristics and outcome measures) will be made available upon reasonable request to qualified researchers.

Data will be available after publication of the main results for a period of 3 years.

Requests should be directed to the corresponding author (Assoc. Prof. Sedat Arslan, Bandirma Onyedi Eylul University; email: sarslan@bandirma.edu.tr).

No identifying participant information will be shared. Supporting documents such as the study protocol, statistical analysis plan, and informed consent form will also be provided upon request.

Tidsram för IPD-delning

Deidentified IPD and supporting documents will be available beginning 1 month after publication of the primary results and for 36 months thereafter. If publication is delayed, access will begin 12 months after database lock. Extensions may be granted upon justified request.

Kriterier för IPD Sharing Access

Qualified researchers with a methodologically sound proposal may request access by emailing the corresponding author (Assoc. Prof. Sedat Arslan; sarslan@bandirma.edu.tr). Requests must include a brief protocol, objectives, analysis plan, and IRB/ethics determination (if applicable). A data use agreement is required. Only deidentified IPD (baseline characteristics and prespecified outcomes) and documentation (protocol, SAP, ICF templates, analytic code) will be shared. Data will be provided via a secure institutional repository link; re-identification and commercial use are prohibited.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • ANALYTIC_CODE

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera